The global health crisis of the early 2020s exposed the vulnerabilities of overly extended supply chains, leading many European pharmaceutical companies to rethink their outsourcing strategies. There is a growing trend toward "nearshoring" or domestic outsourcing, where trials are kept within Europe rather than being moved to lower-cost regions in Asia. This shift is driven by a desire for...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt